Loading
OP
OncoMed Pharmaceuticals Inc Stock: price and insider trades · United States
OncoMed Pharmaceuticals Inc: what insiders have been doing
This page follows insider dealings at OncoMed Pharmaceuticals Inc as filed with SEC (Form 4). Nothing new has been filed by managers of OncoMed Pharmaceuticals Inc in twelve months, the latest record being from 12 January 2016.
Other companies in the same market with recent insider buying flagged by our signals: Relmada Therapeutics, Inc. and Uber Technologies, Inc. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
22
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
n/a
21 ops. · all time
Financial data
as of FY 2018FY ended December 2018 · cache
Income statement
RevenueUS$38.5M
Net income-US$7M-18.2% margin
Last declaration on 12 January 2016
Declarations22 total
2,500 sharesCommon StockSEC:0001140361-16-047651:0
2,500 sharesCommon StockSEC:0001140361-16-047651:1
2,092 sharesCommon StockSEC:0001140361-16-047340:0
69 sharesCommon StockSEC:0001140361-16-047340:1
1 sharesCommon StockSEC:0001140361-16-047340:2
2,092 sharesCommon StockSEC:0001140361-16-047339:0
69 sharesCommon StockSEC:0001140361-16-047339:1
1 sharesCommon StockSEC:0001140361-16-047339:2
2,335 sharesCommon StockSEC:0001140361-16-047336:0
77 sharesCommon StockSEC:0001140361-16-047336:1
1,570 sharesCommon StockSEC:0001140361-16-047335:0
52 sharesCommon StockSEC:0001140361-16-047335:1
1 sharesCommon StockSEC:0001140361-16-047335:2
2,092 sharesCommon StockSEC:0001140361-16-047337:0
69 sharesCommon StockSEC:0001140361-16-047337:1
1 sharesCommon StockSEC:0001140361-16-047337:2
2,092 sharesCommon StockSEC:0001140361-16-047333:0
69 sharesCommon StockSEC:0001140361-16-047333:1
1 sharesCommon StockSEC:0001140361-16-047333:2
2,092 sharesCommon StockSEC:0001140361-16-047334:0
69 sharesCommon StockSEC:0001140361-16-047334:1
1 sharesCommon StockSEC:0001140361-16-047334:2
22 of 22 declarations
About OncoMed Pharmaceuticals Inc
OncoMed Pharmaceuticals Inc is a biopharmaceutical company focused on developing innovative therapies for cancer treatment. It specializes in the discovery and development of drugs targeting tumor stem cells.
